Healthcare · Biotechnology
Price
$11.00
Market Cap
$598.4M
Employees
18
Beta
0.09
Avg Volume
1,402,909
CEO
Ilya Rachman
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Runs with full report
Price Overview
Last updated: Jul 8, 2026 7:17pm (just now)
Current data · timestamped when a report runs
$11.00
Change · Jul 8
-1.02 (-8.49%)
Day Range
$10.71 – $12.00
52-Week Range
$1.94 – $12.14
50-Day MA
$9.30
200-Day MA
$6.74
Volume
2,429,244.00
Analyst Price Targets
Low
$14.00
Consensus
$17.00
High
$20.00
(5 analysts)
Share Structure
Outstanding
54,401,897.00
Float
43,398,554.00
Free Float
79.8%
Normal free float
— 79.8% of shares trade freely, ~20.2% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-12.36
Stock Price: $11.00
EPS (Diluted): -0.89
EPS (Diluted): -0.89
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.84
Stock Price: $11.00
Total Equity: $93.80M
Shares: 32,965,706
Total Equity: $93.80M
Shares: 32,965,706
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-15.05
Market Cap: $598.42M
Total Debt: $0.00
Cash: $93.93M
EBITDA: -$29.04M
Total Debt: $0.00
Cash: $93.93M
EBITDA: -$29.04M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$79.6M
Market Cap: $598.42M
Total Debt: $0.00
Cash: $93.93M
Total Debt: $0.00
Cash: $93.93M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $11.00
Revenue: $0.00
Shares: 32,965,706
Revenue: $0.00
Shares: 32,965,706
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$364,501
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$27.21M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$29.44M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-73.2%
Net Income: -$29.44M
Total Equity: $93.80M
Total Equity: $93.80M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-42.3%
Operating Income: -$27.21M
Tax Rate: -0.1%
Equity: $93.80M
Total Debt: $0.00
Cash: $93.93M
Tax Rate: -0.1%
Equity: $93.80M
Total Debt: $0.00
Cash: $93.93M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
10.01
Current Assets: $101.24M
Current Liabilities: $10.11M
Current Liabilities: $10.11M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $93.80M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $93.80M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 32,965,706
Shares: 32,965,706
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.85
Total Equity: $93.80M
Shares: 32,965,706
Shares: 32,965,706
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.75
Operating CF: -$23.93M
CapEx: -$732,925
Shares: 32,965,706
CapEx: -$732,925
Shares: 32,965,706
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $11.00
Stock Price: $11.00
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$29.44M
Net Income: -$29.44M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares IMMX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $364,501 |
| Gross Profit | $0 | $0 | $0 | $0 | $-364,501 |
| Operating Expenses | $1.4M | $8.2M | $16.1M | $22.7M | $26.8M |
| Operating Income | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$27.2M |
| Net Income | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| EBITDA | -$24.2M | -$8.2M | -$15.6M | -$21.5M | -$29.0M |
| EPS | $-6.64 | $-0.59 | $-0.89 | $-0.76 | $-0.89 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $17.6M | $13.4M | $17.5M | $17.7M | $93.9M |
| Total Current Assets | $18.2M | $14.9M | $19.8M | $20.2M | $101.2M |
| Total Assets | $18.2M | $14.9M | $19.9M | $22.9M | $104.8M |
| Current Liabilities | $202,039 | $1.3M | $3.7M | $8.7M | $10.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $202,039 | $1.7M | $3.7M | $9.7M | $11.0M |
| Total Equity | $18.0M | $13.2M | $16.4M | $13.3M | $93.8M |
| Retained Earnings | -$29.8M | -$38.0M | -$53.4M | -$75.0M | -$104.5M |
Cash Flow (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.6M | -$7.4M | -$11.4M | -$14.6M | -$23.9M |
| Capital Expenditure | $-802 | $3 | $-52,089 | -$1.2M | $-732,925 |
| Free Cash Flow | -$1.6M | -$7.4M | -$11.4M | -$15.8M | -$24.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $-99,963 | $0 | $0 | $0 |
| Net Change in Cash | $17.3M | -$4.2M | $4.1M | $172,163 | $76.2M |
Analyst Estimates (Annual)
Last updated: Jul 8, 2026 7:17pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$37.6M $25.4M – $49.8M
|
$178.6M $178.6M – $178.6M
|
$313.4M $211.6M – $415.2M
|
$481.0M $324.7M – $637.4M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$22.6M -$42.3M – -$2.9M
|
-$12.5M -$21.3M – -$3.7M
|
$9.2M $5.3M – $13.1M
|
$61.1M $35.3M – $86.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -507.9% | -96.4% | -40.5% | -20.0% |
| Net Income Growth | +66.2% | -87.4% | -40.1% | -36.2% |
| EBITDA Growth | +66.0% | -89.4% | -38.4% | -34.8% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-22 | Adams Helen C. | A-Award | 6,250.00 | $0.00 | $0 |
| 2026-05-22 | Adams Helen C. | A-Award | 12,500.00 | $8.78 | $109,750 |
| 2026-05-22 | Ng Carey | A-Award | 6,250.00 | $0.00 | $0 |
| 2026-05-22 | Ng Carey | A-Award | 12,500.00 | $8.78 | $109,750 |
| 2026-05-22 | Marquet Magda | A-Award | 6,250.00 | $0.00 | $0 |
| 2026-05-22 | Marquet Magda | A-Award | 12,500.00 | $8.78 | $109,750 |
| 2026-05-22 | Morris Gabriel S | A-Award | 500,000.00 | $8.78 | $4.4M |
| 2026-05-22 | CHANG NANCY T | A-Award | 6,250.00 | $0.00 | $0 |
| 2026-05-22 | CHANG NANCY T | A-Award | 12,500.00 | $8.78 | $109,750 |
| 2026-05-22 | Rachman Ilya M | A-Award | 500,000.00 | $8.78 | $4.4M |
| 2026-05-22 | Chudnovsky Yekaterina | A-Award | 12,500.00 | $8.78 | $109,750 |
| 2026-05-22 | Chudnovsky Yekaterina | A-Award | 6,250.00 | $0.00 | $0 |
| 2026-05-22 | Hsu Jason | A-Award | 6,250.00 | $0.00 | $0 |
| 2026-05-22 | Hsu Jason | A-Award | 12,500.00 | $8.78 | $109,750 |
| 2026-05-22 | BUCHAN JANE | A-Award | 6,250.00 | $0.00 | $0 |
| 2026-05-22 | BUCHAN JANE | A-Award | 12,500.00 | $8.78 | $109,750 |
| 2025-11-21 | CHANG NANCY T | A-Award | 39,643.00 | $4.33 | $171,654 |
| 2025-12-10 | Rachman Ilya M | P-Purchase | 746.00 | $6.67 | $4,976 |
| 2025-12-08 | Morris Gabriel S | X-InTheMoney | 156,000.00 | $0.80 | $124,800 |
| 2025-12-10 | Morris Gabriel S | P-Purchase | 770.00 | $6.58 | $5,067 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for IMMX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for IMMX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.392 · 5bda1781 · 2026-07-08 16:12:24